SOURCE: Medivation, Inc.

Medivation, Inc.

April 29, 2011 08:00 ET

Medivation Announces Upcoming Teleconference, Webcasts and Conference Participation

SAN FRANCISCO, CA--(Marketwire - Apr 29, 2011) - Medivation, Inc. (NASDAQ: MDVN) today announced that it will hold the following events in May:

  • A teleconference and webcast with management to discuss first quarter 2011 financial results and provide a general business update on Friday, May 6, 2011 at 4:30 p.m. Eastern Time. A press release for the first quarter ended on March 31, 2011 will be released after markets close on May 6, 2011.

    Interested parties may call 877-303-2523 from the U.S. or +1-253-237-1755 internationally. Individuals interested in listening to the live call via webcast may do so by visiting A replay of the webcast will be available on the Company's website for 30 days.

  • Patrick Machado, Medivation's chief business and financial officer, will present at the Bank of America Merrill Lynch Health Care Conference on Wednesday, May 11, 2011 at 1:40 p.m. Pacific Time at the Encore at Wynn Las Vegas. During the corporate presentation, Mr. Machado will provide an overview of Medivation and its clinical development programs for MDV3100 for prostate cancer and dimebon for Alzheimer's disease.

    A live audio webcast of the corporate presentation will be available on the "Events and Presentations" page of the "Investor Relations" section of the Company's website at A replay also will be available for 30 days following the live presentation.

About Medivation

Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers. Together with its corporate partners Astellas and Pfizer, Medivation currently has investigational drugs in Phase 3 development to treat advanced prostate cancer and mild-to-moderate Alzheimer's disease. For more information, please visit us at